Disease · MONDO_0006192

endometrial endometrioid adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. endometrial endometrioid adenocarcinoma. Diseases, record MONDO_0006192. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006192

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: endometrial endometrioid adenocarcinoma; Open Targets
Open Targets ID: MONDO_0006192; Open Targets
Other names: endometrioid adenocarcinoma of endometrium, endometrioid adenocarcinoma of the endometrium, endometrioid carcinoma of endometrium, endometrioid carcinoma of the endometrium, endometrioid endomet. adenocar., endometrioid endometrial adenocarcinoma, uterine corpus endometrioid adenocarcinoma, uterine corpus endometrioid carcinoma; Open Targets
NCI Thesaurus: C6287; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 4 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TAZEMETOSTAT	CHEMBL3414621	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENTINOSTAT	CHEMBL27759	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
EZH2	Histone-lysine N-methyltransferase EZH2	1	Histone-lysine N-methyltransferase EZH2 inhibitor	Phase 2	https://conductscience.org/library/genes/2146	Drugs and targets
HDAC1	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC10	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC2	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC4	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/10014	Drugs and targets
HDAC6	Histone deacetylase	1	Histone deacetylase inhibitor	Early phase 1	https://conductscience.org/library/genes/10013	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00064025	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Phase 2	75	2014-08-15	Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer	MEDROXYPROGESTERONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03348631	Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	Phase 2	62	2025-03-06	Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma	TAZEMETOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03018249	Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer	Early phase 1	50	2021-06-02	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma	ENTINOSTAT, MEDROXYPROGESTERONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04439214	Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)	Phase 2	47	2021-04-06	Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT05023655	Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation	Phase 2	20		Solid Tumor, ARID1A Gene Mutation	TAZEMETOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT06278857	SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)	Phase 2	10		Endometrial Cancer Stage I, Mmr Deficiency, Endometrioid Endometrial Adenocarcinoma, Immune-related Adverse Event	DOSTARLIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients vs Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients: Number of Patients With a Grade 3 (or Higher) Adverse Events	6 of 16	20 of 42	58	NCT03348631	Trial comparisons
Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients vs Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients: deaths from any cause	11 of 16	28 of 42	58	NCT03348631	Trial comparisons
Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients vs Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients: serious adverse events	3 of 16	12 of 42	58	NCT03348631	Trial comparisons
Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: deaths from any cause	0 of 23	0 of 23	46	NCT03018249	Trial comparisons
Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: serious adverse events	1 of 23	1 of 23	46	NCT03018249	Trial comparisons
Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: Percent of Participants With a Ki67 Response	15 of 22	18 of 20	42	NCT03018249	Trial comparisons
Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: Percentage of Participants With a Histologic Response	16 of 22	14 of 20	42	NCT03018249	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31765263	RESULT	1	PubMed
39955187	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006192

GET https://conductscience.org/api/diseases/v1/MONDO_0006192/drugs

API reference For AI assistants